Molnupiravir speeds up recovery and eases long-term symptoms, but its minimal effect on hospitalizations raises questions about its broader impact on COVID-19 care. Study: Health outcomes 3 months and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The antiviral reduced the risk for severe symptoms of ...

In patients hospitalized with COVID-19, adding molnupiravir or nirmatrelvir-ritonavir to usual care was not associated with improved clinical outcomes, including 28-day mortality duration of hospital ...

NEW YORK (WABC) -- With two new pills now authorized by the FDA to fight the effects of COVID, there's a push for New York state to be first in line for the initial shipments. Supplies of Pfizer's ...

Starting antiviral treatment as late as 14 days after infection with SARS-CoV-2 may still be beneficial in hosts with compromised immune systems, who are at greatest risk of developing severe COVID-19 ...